Researchers at the American Psychiatric Association (APA) annual meeting in San Francisco presented preliminary findings showing that the impact of cannabis legalization on psychosis remains unclear. Occurring amid ongoing federal rescheduling efforts, the systematic review highlights a frustrating disconnect between worsening clinical cases and mixed public health data.
Dr. Jeonghyun Shin of Maimonides Medical Center noted that across the 33 studies reviewed, cannabis dose and the age of first use play critical roles in determining psychosis risk. However, translating these individual risks into broad policy impacts has proven difficult.
The review identified several alarming trends regarding individual cannabis use:
- Daily use of high-potency cannabis (over 10% THC) increases the odds of developing a psychotic disorder by nearly five times compared to non-users.
- Initiating cannabis use by age 15 is directly tied to an earlier onset of psychosis compared to those who start later in life.
Despite these clear individual risk signals, data evaluating state policies that legalize cannabis have returned null or mixed results regarding psychosis-related outcomes. Dr. Shin identified this discrepancy as a "critical" research gap that requires immediate further study as policy rapidly evolves.
Co-author Dr. Jamie Baik of Cambridge Health Alliance noted a stark contrast between clinical practice and current statistical data. While practitioners frequently observe cannabis worsening psychiatric symptoms and outcomes, these realities are not immediately reflected in broader studies.
Dr. Baik suggested that age grouping might be masking the true impact of legalization. While adolescent use (up to age 18) did not significantly increase post-legalization, young adults aged 19 to 25 appear to be disproportionately affected. Lumping these transitional-age youths together in studies often dilutes significant findings.
This research arrives as the U.S. government navigates complex cannabis rescheduling. In April, state-licensed medical marijuana shifted from a Schedule I to a less strictly regulated Schedule III substance, easing research barriers. A broader Drug Enforcement Agency hearing on recreational cannabis is slated for June.
The systematic review analyzed peer-reviewed literature published through January 2026, focusing on THC, cannabis, and synthetic cannabinoids. The scope of the 33 included studies varied:
- 11 studies focused on individuals with psychosis or those at high risk.
- 17 studies examined emergency department visits or inpatient hospitalizations associated with psychosis.
- 12 studies looked specifically at outcomes in youths aged 15 to 25.
For their next steps, Dr. Shin’s team plans to extract further data to make definitive conclusions regarding different age groups and outcomes. Ultimately, the question of whether policy changes directly impact psychosis remains unanswered, with researchers urging the medical community to "stay tuned for the final results."
- Reference:
The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study - Daily Use, Especially of High-Potency Cannabis, Drives the Earlier Onset of Psychosis in Cannabis Users
- State Cannabis Legalization and Psychosis-Related Health Care Utilization
